AstraZeneca and Pozen submit EU application for Vimovo

AstraZeneca, in partnership with Pozen, has submitted a marketing authorisation application in the EU for Vimovo (enteric-coated naproxen/immediate-release esomeprazole magnesium) tablets.

The therapy is under investigation for the treatment of the symptoms of osteoarthritis (OA), rheumatoid arthritis and ankylosing spondylitis for those at risk of developing ulcers due to them being subscribed non-steroidal anti-inflammatory drugs (NSAIDs).

Lori Kreamer, global product vice-president at AstraZeneca, commented: “If approved, Vimovo may provide OA patients at risk of NSAID-associated ulcers a new treatment option that offers both enteric-coated naproxen and immediate-release esomeprazole in a single pill.”

Earlier this month, AstraZeneca was granted permission by the European commission to market Onglyza in 27 EU countries in collaboration with Bristol-Myers Squibb.

Onglyza is a once-daily oral tablet which is distributed in 5 mg doses and used in adult patients with type 2 diabetes.